Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

NCT06046482 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Head Neck
Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Pembrolizumab
DRUG: Magrolimab
DRUG: cetuximab
DRUG: Docetaxel

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]